Lisa Anne Bero, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lisa Anne Bero, PhD

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Box 0613, UCSF

UCSF Profiles

Cancer Center Membership

Program Member » Tobacco Control

Research Summary

Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing bias in the design, conduct and dissemination of research on pharmaceuticals, tobacco and chemicals. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. Her international activities include advisor to the World Health Organization Department of Essential Medicines and Pharmaceutical Policies, member and chair of the WHO Essential Medicines Committee and member of the Pan American Health Organization Advisory Committee on Health Research. She is Director of the San Francisco Branch of the United States Cochrane Center and the World Health Organization Collaborating Centre on Pharmaceutical Research and Science Policy. She was an elected member of the Cochrane Collaboration Steering Group for 12 years and was appointed Co-Chair in 2013. Dr. Bero serves on several national and international committees related to conflicts of interest and research, such as the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education and Practice.

Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)


Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Mandrioli D, Kearns CE, Bero LA. Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews. PLoS One. 2016; 11(9):e0162198.
    View on PubMed
  2. Apollonio DE, Wolfe N, Bero LA. Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. BMC Public Health. 2016; 16(1):822.
    View on PubMed
  3. Vandenberg LN, Ågerstrand M, Beronius A, Beausoleil C, Bergman Å, Bero LA, Bornehag CG, Boyer CS, Cooper GS, Cotgreave I, Gee D, Grandjean P, Guyton KZ, Hass U, Heindel JJ, Jobling S, Kidd KA, Kortenkamp A, Macleod MR, Martin OV, Norinder U, Scheringer M, Thayer KA, Toppari J, Whaley P, Woodruff TJ, Rudén C. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals. Environ Health. 2016; 15(1):74.
    View on PubMed
  4. Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, Campbell M, Donald JM, Sen S, Bero L, Zeise L, Woodruff TJ. Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. Environ Int. 2016 Jul-Aug; 92-93:716-28.
    View on PubMed
  5. Grundy Q, Bero LA, Malone RE. Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry. Ann Intern Med. 2016 Jun 7; 164(11):733-9.
    View on PubMed
  6. Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Ghersi D, Guyatt G, Hooijmans C, Langendam M, Mandrioli D, Mustafa RA, Rehfuess EA, Rooney AA, Shea B, Silbergeld EK, Sutton P, Wolfe MS, Woodruff TJ, Verbeek JH, Holloway AC, Santesso N, Schünemann HJ. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int. 2016 Jul-Aug; 92-93:611-6.
    View on PubMed
  7. Bero L, Anglemyer A, Vesterinen H, Krauth D. The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis. Environ Int. 2016 Jul-Aug; 92-93:597-604.
    View on PubMed
  8. Tuller D, Bero L. Big Tobacco and Drugstore Chains: A Long, Cozy Relationship. JAMA Oncol. 2015 Dec 1; 1(9):1215-6.
    View on PubMed
  9. Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 5; 527(7576):31-2.
    View on PubMed
  10. Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Schünemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Feb; 70:111-22.
    View on PubMed
  11. Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015; 350:h2613.
    View on PubMed
  12. Tran DN, Bero LA. Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. J Glob Health. 2015 Jun; 5(1):010406.
    View on PubMed
  13. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, Bero L, McCaffery K. Public Opinions about Overdiagnosis: A National Community Survey. PLoS One. 2015; 10(5):e0125165.
    View on PubMed
  14. Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098.
    View on PubMed
  15. Siler K, Lee K, Bero L. Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):E1512.
    View on PubMed
  16. Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015; 15:12.
    View on PubMed
  17. Chiu Y, Bero L, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015 Jun; 119(6):802-13.
    View on PubMed
  18. Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 1; 93(1):4.
    View on PubMed
  19. Siler K, Lee K, Bero L. Measuring the effectiveness of scientific gatekeeping. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):360-5.
    View on PubMed
  20. Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, Schünemann HJ, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. J Clin Epidemiol. 2016 Apr; 72:98-106.
    View on PubMed

Go to UCSF Profiles, powered by CTSI